Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study.
Kim JG, Sohn SK, Chae YS, Cho YY, Yang DH, Lee JJ, Kim HJ, Shin HJ, Chung JS, Cho GJ, Lee WS, Joo YD, Sohn CH, Oh SJ.
Kim JG, et al. Among authors: chae ys.
Cancer Chemother Pharmacol. 2007 Jun;60(1):129-34. doi: 10.1007/s00280-007-0469-9. Epub 2007 Apr 4.
Cancer Chemother Pharmacol. 2007.
PMID: 17406867
Clinical Trial.